MetaCap

Dianthus Therapeutics (DNTH) vs Veradermics (MANE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Veradermics is the larger company by market cap ($5.04 billion vs $4.76 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DNTH+75.67%MANE+216.61%
+331%+156%-19%
Feb 4, 20261 yearNov 20, 2026
DNTH+66.60%MANE+210.60%
+277%+128%-20%
Feb 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DNTH versus MANE key metrics
MetricDNTHMANE
Share price$84.55$119.52
Market cap$4.76B$5.04B
1-day change-0.33%-3.92%
YTD return+105.17%—
1-year return+103.98%—
5-year return-12.80%—
EPS (TTM)$-4.08$-3.89
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$2.04M—
Revenue growth (YoY)-67.35%—
Net income (latest FY)$-162.34M$-70.00M
Operating margin-8739.34%—
Net margin-7973.33%—
52-week high$117.88$156.63
52-week low$35.84$32.00
Distance from 52-week high-28.27%-23.69%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+64.70%+56.74%
Average volume848.96K738.22K
Shares outstanding56.31M42.20M
Employees9251
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Dianthus Therapeutics

DNTH stock →

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.

Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees

About Veradermics

MANE stock →

Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children.

Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees

DNTH vs MANE FAQ

Which is bigger, Dianthus Therapeutics or Veradermics?

Veradermics (MANE) is larger, with a market capitalization of $5.04B compared with $4.76B for Dianthus Therapeutics (DNTH).

Are Dianthus Therapeutics and Veradermics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons